Clinical trial
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
NCT04272125 is registered in ClinicalTrials.gov with Chongqing Precision Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
- Lead sponsor
- Chongqing Precision Biotech Co., Ltd
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- December 1, 2019
- Completion date
- July 1, 2024
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.